Halozyme Therapeutics (HALO) Announces 5.2 Million Common Share Offering
More News related to HALO
- ProMetic and Halozyme Enter Into Long-Term Supply Agreement
- Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme
- Halozyme (HALO) posts Q3 Loss of 16c, Beats by 2c
- Halozyme Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/06: American International (AIG), Scripps (SNI), Suncor Energy (SU), Blackstone Group (BX) Report
More News related to Equity Offerings
- Cisco (CSCO) Announces Pricing for Unsecured Senior Notes at $5B
- Schweitzer-Mauduit (SWM) Announces 1.8M Common Share Offering
- Thomas Weisel Partners (TWPG) Files $100M Mixed Shelf
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- IPG Photonics Corp (IPGP) Files $130M Mixed Shelf
Halozyme Therapeutics, Inc. (Nasdaq: HALO) intends to offer up to 5,200,000 shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets.[SM]
Related Categories
Equity OfferingsStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
